This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of teriflunomide
MSMED_TERIFLUNOMIDE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
425 |
4. Check minimum number of events
Min. number of events
3
|
425 |
5. Include endpointsNone |
425 |
6. Filter based on genotype QC (FinnGen only) |
381 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of teriflunomide
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- L04AA Selective immunosuppressants
- Other degenerative diseases of the nervous system
- ILD medications: immunosuppressive drugs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 381 | 284 | 97 |
| Unadjusted period prevalence (%) | 0.09 | 0.10 | 0.04 |
| Median age at first event (years) | 44.65 | 45.13 | 43.28 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 404
- Matched controls
- 4040
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
38.6
323.3
279
221
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
146.5
317.5
160
18
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
5493.1
307.7
391
22
L03AB07
ATC
interferon beta-1a; parenteral
255.3
307.7
190
14
109
Kela drug reimbursment
Multiple sclerosis
4503599627370496.0
307.7
402
21
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
404
32
L04AA31
ATC
[U] teriflunomide
+∞
307.7
404
*
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
307.7
404
21
N86
ICPC
Multiple sclerosis
172.2
277.5
137
12
H46
ICD-10 Finland
Optic neuritis
92.7
254.7
136
22
TAB00
NOMESCO Finland
Lumbar puncture
29.5
225.3
173
100
L04AK02
ATC
teriflunomide; oral
+∞
198.9
174
*
L04AX07
ATC
dimethyl fumarate; oral
125.6
188.8
96
10
N04BB01
ATC
amantadine; oral
77.3
174.5
95
16
C10AC01
ATC
colestyramine; oral
32.7
172.2
119
51
L03AX13
ATC
glatiramer acetate; parenteral
263.5
143.1
139
8
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
10.2
106.8
154
230
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
32.9
96.6
64
23
G04BD12
ATC
mirabegron; oral
11.3
93.2
114
136
L03AB08
ATC
interferon beta-1b; parenteral
280.2
89.4
88
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
23.7
88.1
66
33
M03BX01
ATC
baclofen; systemic
19.7
83.3
68
41
XA800
NOMESCO Finland
Neuropsychological investigation
10.7
81.7
102
124
164
Kela drug reimbursment
Fingolimod
124.3
76.1
80
8
N07XX09
ATC
[U] dimethyl fumarate
189.5
76.0
77
5
G04BD09
ATC
trospium; oral
33.9
73.7
48
16
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
20.1
73.6
59
34
XKD00
NOMESCO Finland
Uroflowmetry
11.2
72.6
85
94
XCK00
NOMESCO Finland
Perimetry
13.1
71.5
74
68
XKD06
NOMESCO Finland
Physiologic investigation of micturition
20.8
71.1
56
31
353
Kela drug reimbursment
Cladribine and fingolimod
122.7
67.4
71
7
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.6
60.6
88
127
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
10.4
60.1
73
84
R20.2
ICD-10 Finland
Paraesthesia of skin
6.2
50.3
102
208
G04BD08
ATC
solifenacin; oral
10.3
47.1
56
62
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
10.6
46.4
54
58
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.7
44.2
137
399
L04AA27
ATC
[U] fingolimod
90.6
43.9
48
6
ZX120
NOMESCO Finland
Intravenous
6.1
41.0
82
163
L04AG12
ATC
ofatumumab; parenteral
426.9
39.8
39
*
L03AB13
ATC
peginterferon beta-1a; parenteral
414.7
38.7
38
*
H02AB04
ATC
methylprednisolone; systemic
4.6
37.4
110
304
2AB04, ,
NOMESCO Finland
83.8
34.5
38
5
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
9.6
34.3
42
48
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
98.6
33.3
36
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
5.6
31.4
66
136
XKC03
NOMESCO Finland
Water cystometry
9.9
27.8
33
36
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
9.6
27.2
33
37
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.6
27.1
73
185
UKC02
NOMESCO Finland
Cystoscopy
4.6
26.6
71
179
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.4
26.4
57
120
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
10.4
26.2
30
31
G04BD07
ATC
tolterodine; oral
9.1
26.1
33
39
L04AA40
ATC
cladribine; oral
144.3
25.9
27
*
R1250
NOMESCO Finland
Evaluation of functional capability
7.8
25.0
36
50
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
24.2
23
*
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
35.9
23.7
30
9
N06BA07
ATC
modafinil; oral
30.4
23.5
31
11
R35
ICD-10 Finland
Polyuria
5.4
22.6
48
99
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
39.5
21.0
26
7
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
17.0
21.0
33
21
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
116.1
20.8
22
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
220.9
20.8
21
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.4
20.4
56
143
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
50.8
20.4
24
5
N03AX12
ATC
[U] gabapentin; oral
3.2
19.9
98
371
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.0
19.7
45
99
H53.2
ICD-10 Finland
Diplopia
7.1
19.4
30
45
Z2445
NOMESCO Finland
Psychologist
4.5
19.0
49
119
TKC22
NOMESCO Finland
Catheterisation instruction
20.6
18.4
27
14
N06AX16
ATC
venlafaxine; oral
2.8
17.5
112
488
N02BF01
ATC
gabapentin; oral
3.3
16.7
73
256
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.6
16.4
32
61
SPAT1229
SPAT
Assessment of need for aid
5.4
16.3
33
65
N03AE01
ATC
clonazepam; systemic
4.5
15.5
40
97
Z3226
NOMESCO Finland
Physiotherapist
2.7
15.3
97
417
R4110
NOMESCO Finland
Physiotherapy
2.4
14.8
134
684
H53.1
ICD-10 Finland
Subjective visual disturbances
3.5
14.4
53
166
G04BD04
ATC
oxybutynin; oral, transdermal
5.0
14.3
32
69
R33
ICD-10 Finland
Retention of urine
5.7
14.2
27
50
N03AX16
ATC
[U] pregabalin
2.5
13.9
112
540
XCD10
NOMESCO Finland
Electrophysiological examination of eye
10.2
13.4
26
27
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
13.8
12.6
21
16
R4150
NOMESCO Finland
Neuropsychological rehabilitation
9.4
12.4
25
28
L28
ICPC
Limited function/disability (L)
2.8
12.3
67
264
A02BC02
ATC
pantoprazole; systemic
2.2
11.7
282
2074
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
66.9
11.7
13
*
TKC20
NOMESCO Finland
Catheterisation of bladder
4.5
11.5
29
69
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
28.9
10.8
14
5
Z3231
NOMESCO Finland
Registered nurse
2.2
10.7
123
681
XKD03
NOMESCO Finland
Urethral pressure profilometry
10.0
10.4
20
21
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.4
10.3
26
62
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.7
10.1
59
241
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
41.2
10.0
12
*
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.3
10.0
40
132
4AA23, ,
NOMESCO Finland
56.4
9.7
11
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.5
9.5
69
313
M03BX02
ATC
tizanidine; oral
2.1
9.5
297
2313
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
102.3
9.5
10
*
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
102.3
9.5
10
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.6
9.4
61
262
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
9.4
9
*
R4120
NOMESCO Finland
Occupational therapy
3.1
9.4
42
148
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
8.0
9.2
20
26
A28
ICPC
Limited function/disability NOS
2.9
9.2
44
161
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
9.2
100
538
J01EA01
ATC
trimethoprim; systemic
2.0
9.2
120
692
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.8
8.7
27
75
G04BD11
ATC
fesoterodine; oral
10.4
8.6
16
16
CS494
NOMESCO Finland
Other visual field testing
8.8
8.4
17
20
R42
ICD-10 Finland
Dizziness and giddiness
2.2
8.4
85
444
N04BD01
ATC
selegiline; oral
17.6
8.1
12
7
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
34.1
8.1
10
*
G04CA02
ATC
tamsulosin; oral
2.8
8.1
41
155
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
4.2
7.9
21
52
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
4.5
7.8
19
44
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
7.9
7.5
16
21
G37.8
ICD-10 Finland
Other specified demyelinating diseases of central nervous system
81.5
7.4
8
*
SPAT1216
SPAT
Assessment of functional ability
2.5
7.2
45
190
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
6.5
7.0
17
27
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
11.2
6.8
12
11
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
9.6
6.8
13
14
L04AE01
ATC
fingolimod; oral
40.8
6.8
8
*
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
23.0
6.7
9
*
R5110, ,
SPAT
2.8
6.7
33
123
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.6
6.6
38
154
N06AX12
ATC
bupropion; oral
2.3
6.5
54
258
R39.1
ICD-10 Finland
Other difficulties with micturition
6.4
6.5
16
26
N02BF02
ATC
pregabalin; oral
2.6
6.5
37
149
L04AX09
ATC
diroximel fumarate; oral
70.9
6.4
7
*
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.8
6.2
32
122
N28
ICPC
Limited function/disability (N)
10.2
6.1
11
11
U13
ICPC
Bladder symptom/complaint other
5.7
6.1
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
153
71
34.08
217.27
1.2
1.1
—
—
—
0
0
89
27
41.99
142.84
1.0
1.1
—
—
—
0
0
90
35
32.80
133.54
1.0
1.1
212.18
223.00
mg/l
0.20
75
29
90
36
31.88
132.21
1.1
1.1
54.33
32.68
mg/l
3.94
71
30
139
137
14.94
132.04
2.1
1.6
0.03
0.02
iu/ml
—
6
15
190
295
11.27
130.06
4.0
2.8
9.59
10.58
g/l
3.77
177
280
76
30
30.97
111.61
1.2
1.1
1.01
0.52
ratio
8.17
42
17
68
25
32.50
102.04
1.2
1.1
1606.93
1795.80
miu/ml
0.36
68
25
74
42
21.35
93.59
1.0
1.1
—
—
—
0
0
395
2060
42.12
93.29
15.6
9.7
3.24
3.98
e9/l
20.37
380
1809
75
45
20.24
92.41
1.0
1.1
—
—
—
0
0
88
6
186.75
87.00
1.8
4.0
—
—
—
0
0
72
45
19.25
86.84
1.0
1.1
—
—
—
0
0
61
28
25.48
84.14
1.0
1.1
0.97
1.25
u/l
0.88
19
11
89
93
11.99
79.31
1.1
1.3
145.70
16.52
e6/l
0.47
74
67
89
93
11.99
79.31
1.2
1.3
61.68
176.44
e6/l
0.57
75
70
57
27
24.41
77.50
2.7
2.4
435.61
499.55
e6/l
0.54
49
22
67
47
16.89
75.91
1.3
1.1
—
—
—
0
0
125
239
7.13
67.03
3.8
1.7
0.90
1.34
g/l
2.99
125
228
45
29
17.34
52.81
3.0
2.1
0.87
0.82
e9/l
0.22
45
29
40
23
19.19
49.53
3.2
2.7
—
—
—
0
0
51
6
97.08
47.07
1.2
1.0
—
—
—
0
0
199
785
4.03
42.02
4.1
2.5
0.11
0.26
e6/l
1.50
172
541
288
1552
3.98
36.43
2.8
2.6
97.07
73.43
nmol/l
20.11
282
1481
105
297
4.43
34.38
2.6
2.3
36.48
16.19
au/ml
—
6
37
326
2070
3.98
28.75
7.8
3.7
—
560.48
—
0
27
120
458
3.30
24.54
4.0
2.3
0.90
0.94
e6/l
0.06
72
207
106
440
2.91
18.17
4.0
2.4
6.45
3.14
e6/l
1.49
57
191
273
1829
2.52
16.75
6.0
3.1
0.00
0.00
estimate
-0.00
77
367
271
1811
2.51
16.70
6.0
3.1
0.00
0.00
estimate
0.50
75
369
273
1840
2.49
16.36
6.0
3.1
0.00
0.03
estimate
1.08
75
351
52
173
3.30
12.83
1.4
1.4
—
—
—
0
0
203
1294
2.14
12.64
3.7
4.5
38.99
37.62
g/l
5.30
196
1240
68
267
2.86
12.61
3.0
2.2
52.81
4904.81
u/l
2.05
21
117
251
1777
2.09
11.37
2.5
4.4
5.85
6.35
mmol/l
8.23
240
1661
23
29
8.34
10.74
3.6
3.1
51.12
45.82
%
0.57
16
11
47
172
2.96
9.84
2.0
2.3
68.61
68.58
g/l
0.02
47
164
147
923
1.93
8.73
6.6
3.2
0.00
0.01
estimate
0.80
76
360
12
7
17.62
8.12
3.3
2.0
2.72
1.53
ratio
—
12
7
383
3388
3.51
8.12
11.4
9.9
96.62
92.87
ml/min/173m2
4.51
351
3094
313
2563
1.98
7.60
5.3
7.4
73.90
74.76
u/l
0.17
297
2454
393
3555
4.87
7.58
12.2
11.6
16.12
19.62
mg/l
1.81
312
2813
194
1412
1.72
6.61
6.5
2.8
0.00
0.04
estimate
1.64
72
308
13
16
8.35
6.38
1.3
1.6
—
—
—
0
0
398
3752
5.09
6.07
15.6
13.2
67.89
69.83
umol/l
1.08
398
3722
157
1110
1.68
5.75
5.1
2.4
0.01
0.02
estimate
0.07
72
295
357
3164
2.10
5.55
22.3
14.3
13.18
13.31
%
2.22
357
3135
379
3462
2.53
5.10
10.6
11.5
3.89
3.92
mmol/l
1.46
372
3393
21
75
2.90
4.62
1.4
2.5
4.14
2.95
index
—
7
40
331
3574
0.59
3.76
3.6
4.2
1.51
1.47
mmol/l
0.76
315
3453
404
3945
+∞
3.72
29.2
18.1
137.71
137.51
g/l
0.15
404
3924
404
3944
+∞
3.70
29.2
18.4
41.54
41.08
%
2.62
404
3922
404
3943
+∞
3.69
29.0
18.0
90.85
90.20
fl
3.01
404
3923
309
3381
0.63
3.51
3.2
3.6
1.24
1.29
mmol/l
0.53
293
3249
13
37
3.60
3.43
1.4
1.6
—
—
—
0
0
336
3598
0.61
3.27
4.1
4.6
2.95
2.91
mmol/l
0.47
322
3479
167
1328
1.44
3.14
3.3
3.2
29.38
30.58
u/l
0.21
162
1280
6
8
7.59
3.06
1.2
1.1
—
—
—
0
0
6
8
7.59
3.06
1.2
1.4
—
—
—
0
0
6
8
7.59
3.06
1.2
1.3
—
—
—
0
0
8
17
4.78
2.93
1.0
1.0
—
—
—
0
0
15
329
0.43
2.68
1.5
1.5
981.54
1024.22
mu/l
—
10
261
358
3331
1.66
2.68
5.5
5.4
1.59
1.73
mu/l
2.00
346
3232
38
227
1.74
2.50
1.2
1.4
184.80
255.97
miu/ml
—
10
120
7
193
0.35
2.47
1.1
1.4
—
—
—
0
0
338
3582
0.65
2.41
3.7
4.3
4.87
4.84
mmol/l
0.25
323
3473
5
8
6.31
2.38
1.2
1.5
—
—
—
0
0
5
8
6.31
2.38
1.2
1.1
—
—
—
0
0
9
29
3.15
2.24
1.1
1.0
127.89
118.52
pmol/l
—
9
29
5
9
5.61
2.22
1.0
1.9
44.40
45.70
g/l
—
5
9
18
89
2.07
2.09
2.1
2.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
20
3.54
2.06
1.0
1.3
—
—
—
0
0
17
84
2.07
1.98
2.1
1.9
—
—
—
0
0
286
2604
1.34
1.90
3.3
4.1
8.49
8.41
mm/h
0.05
265
2498
7
23
3.08
1.80
1.0
1.2
—
—
—
0
0
75
566
1.40
1.80
1.3
1.6
452.63
73864058.25
pmol/l
1.50
70
528
0
47
0.00
1.71
0.0
2.3
—
5.60
—
0
47
49
674
0.69
1.66
1.9
2.0
3.47
3.48
ratio
0.02
40
529
21
121
1.78
1.61
1.4
1.6
—
—
—
0
0
279
3000
0.77
1.56
3.5
3.8
—
—
—
0
0
56
413
1.41
1.54
2.4
2.2
6.59
6.73
umol/l
0.03
49
364
312
2911
1.32
1.51
4.6
4.6
14.29
14.29
pmol/l
0.00
301
2796
311
3293
0.76
1.50
22.6
14.6
332.16
333.19
g/l
1.47
311
3278
11
214
0.50
1.48
1.9
1.8
—
—
—
0
0
14
74
1.92
1.40
1.0
2.2
0.00
0.00
g/l
-0.00
14
66
54
403
1.39
1.40
1.6
1.9
—
—
—
0
0
129
1504
0.79
1.40
1.7
1.9
1.52
1.43
mmol/l
0.45
113
1359
98
801
1.30
1.39
6.3
3.1
1.02
1.02
kg/l
0.41
68
514
11
208
0.52
1.37
1.3
2.0
1.97
2.92
mg/l
—
6
155
0
37
0.00
1.35
0.0
1.2
—
8.78
—
0
37
6
131
0.45
1.31
2.5
7.1
22.87
24.54
mmol/l
—
6
123
307
3235
0.79
1.22
3.8
4.7
35.20
37.44
mmol/mol
8.35
298
3135
15
248
0.59
1.20
3.4
9.6
-0.20
0.86
mmol/l
—
10
200
108
910
1.25
1.20
1.7
1.5
—
—
—
0
0
28
193
1.48
1.12
3.1
4.1
81.35
78.73
ng/l
0.06
23
179
39
517
0.73
1.09
1.5
1.8
3.47
3.50
mmol/l
0.04
30
377
16
252
0.62
1.07
3.3
9.5
5.09
5.16
kpa
0.13
16
241
16
252
0.62
1.07
3.3
9.5
12.92
13.69
kpa
0.32
16
242
18
273
0.64
1.03
1.2
1.1
0.86
0.90
g/l
0.42
18
273
5
106
0.47
1.02
1.6
1.5
52.80
51.78
ug/l
—
5
106
18
271
0.65
1.00
1.2
1.1
1.64
1.56
g/l
0.75
18
271
5
23
2.19
0.98
1.0
1.2
—
—
—
0
0
10
54
1.87
0.97
1.1
1.1
—
—
—
0
0
39
507
0.74
0.97
1.8
2.1
—
—
—
0
0
138
1221
1.20
0.94
4.1
6.0
1.23
1.21
mmol/l
2.40
129
1143
155
1391
1.19
0.90
5.4
6.7
1.23
1.21
mmol/l
2.38
131
1217
19
275
0.68
0.89
1.8
2.5
15.82
13.54
nmol/l
0.52
19
263
18
261
0.68
0.85
1.1
1.1
0.42
0.64
ratio
—
5
22
6
31
1.95
0.84
1.0
1.5
70.67
69.68
umol/l
—
6
31
11
65
1.71
0.83
1.7
2.2
4.96
5.46
mmol/24h
0.21
11
55
117
1032
1.19
0.82
2.9
2.7
15.54
23.35
ng/l
0.68
67
477
17
247
0.67
0.82
1.6
2.2
15.21
38.10
u/ml
1.57
17
236
8
47
1.72
0.81
1.0
1.2
—
—
—
0
0
118
1043
1.19
0.81
1.9
2.5
47.56
62.76
u/l
2.48
111
988
141
1560
0.85
0.80
2.3
2.6
—
—
estimate
—
0
0
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
0
25
0.00
0.79
0.0
1.6
—
—
—
0
0
18
123
1.49
0.79
2.0
2.9
0.59
0.60
%
0.10
18
123
38
297
1.31
0.79
3.9
3.6
28.91
30.93
%
0.64
32
230
0
26
0.00
0.78
0.0
1.4
—
—
—
0
0
0
26
0.00
0.78
0.0
1.5
—
—
—
0
0
14
209
0.66
0.78
3.5
10.8
131.79
124.97
g/l
0.60
14
202
5
24
2.10
0.74
1.0
1.8
2.02
3.25
mg/l
—
5
24
7
39
1.81
0.73
1.4
1.4
—
—
—
0
0
7
39
1.81
0.73
1.4
1.4
—
—
—
0
0
7
39
1.81
0.73
1.4
1.4
—
—
—
0
0
5
26
1.93
0.71
1.0
1.2
—
—
—
0
0
5
26
1.93
0.71
1.0
1.1
—
—
—
0
0
7
41
1.72
0.70
1.6
1.4
—
—
—
0
0
7
42
1.68
0.68
1.6
1.4
—
—
—
0
0
7
42
1.68
0.68
1.6
1.4
—
—
—
0
0
137
1243
1.15
0.67
1.9
1.8
100.11
98.68
pmol/l
0.14
75
685
32
251
1.30
0.66
1.8
2.7
—
—
—
0
0
8
128
0.62
0.65
4.4
12.0
17.43
16.74
%
—
8
121
8
52
1.55
0.60
1.0
1.1
—
—
—
0
0
8
52
1.55
0.60
1.0
1.1
—
—
—
0
0
0
23
0.00
0.58
0.0
2.1
—
—
—
0
0
0
23
0.00
0.58
0.0
11.3
—
39.40
—
0
10
21
158
1.35
0.58
1.6
1.7
50.63
5.11
u/ml
—
6
47
34
416
0.80
0.57
1.7
2.0
—
—
—
0
0
14
98
1.44
0.57
1.2
1.4
—
—
—
0
0
5
89
0.56
0.56
2.4
2.1
13.20
13.18
%
—
5
89
6
40
1.51
0.52
1.2
1.2
—
—
—
0
0
9
64
1.42
0.52
1.7
3.4
—
5410.00
—
0
5
36
299
1.22
0.50
1.4
1.7
—
—
—
0
0
27
217
1.26
0.49
2.0
1.6
—
—
—
0
0
38
318
1.22
0.49
1.8
2.7
27.63
32.70
u/l
0.78
32
272
24
190
1.28
0.49
1.2
1.8
—
—
—
0
0
21
164
1.30
0.47
1.4
1.7
—
—
—
0
0
5
83
0.60
0.46
1.4
1.7
—
—
—
0
0
52
452
1.17
0.46
1.4
1.4
34.71
25.65
iu/l
0.88
44
395
7
50
1.41
0.45
2.1
1.5
243.57
462.52
pmol/l
—
7
44
30
248
1.23
0.44
2.0
4.4
206.53
233.36
u/l
1.20
30
241
34
285
1.21
0.44
1.4
1.7
—
—
—
0
0
7
51
1.38
0.44
1.3
1.4
—
—
—
0
0
9
130
0.69
0.44
1.6
1.8
—
—
—
0
0
19
240
0.78
0.43
1.6
1.4
—
—
—
0
0
11
151
0.72
0.43
1.6
1.5
—
—
—
0
0
6
92
0.65
0.43
1.2
1.3
4.18
2.90
ug/l
—
6
84
17
132
1.30
0.41
1.1
1.1
3.78
2.42
u/ml
—
8
67
0
17
0.00
0.40
0.0
2.5
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
113
1051
1.10
0.37
2.2
3.1
2.35
2.35
mmol/l
0.02
104
990
189
1979
0.92
0.37
2.7
3.2
100.43
89.96
ug/l
0.53
181
1913
11
146
0.75
0.36
4.2
12.8
96.53
94.15
%
3.85
11
146
6
42
1.43
0.35
1.0
1.2
—
—
—
0
0
6
42
1.43
0.35
1.0
1.2
—
—
—
0
0
6
42
1.43
0.35
1.0
1.2
—
—
—
0
0
5
80
0.62
0.35
1.4
1.6
—
—
—
0
0
10
73
1.38
0.35
1.9
1.5
—
—
—
0
0
6
44
1.37
0.34
2.7
1.9
15.78
17.05
%
—
6
44
6
45
1.34
0.34
1.2
2.4
—
—
—
0
0
24
285
0.83
0.34
3.6
5.2
—
—
—
0
0
19
231
0.81
0.33
1.4
1.5
—
—
—
0
0
11
83
1.33
0.32
1.9
4.4
—
847.14
—
0
7
90
836
1.10
0.31
1.6
1.8
0.41
0.78
mg/l
3.79
63
631
19
228
0.83
0.30
1.2
1.7
0.40
0.33
mg/l
—
9
107
12
93
1.30
0.30
1.4
1.1
1.14
1.50
eliau/ml
—
5
47
8
106
0.75
0.29
2.9
1.5
—
—
—
0
0
37
327
1.14
0.29
2.8
8.1
105.73
104.60
mmol/l
1.27
37
327
58
529
1.11
0.28
2.3
3.1
504.68
343.05
ng/l
0.15
28
289
73
781
0.92
0.23
2.2
2.1
2.48
2.62
mg/l
0.33
65
689
86
809
1.08
0.23
1.9
2.2
—
—
—
0
0
5
40
1.25
0.22
1.0
1.2
—
—
—
0
0
91
860
1.08
0.22
1.3
1.4
13.46
24.36
iu/ml
1.21
17
262
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
7.76
—
0
11
0
10
0.00
0.21
0.0
1.0
—
99.30
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
2.7
—
41.17
—
0
13
0
13
0.00
0.21
0.0
3.5
—
142.85
—
0
13
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
326
3305
0.93
0.20
3.6
3.9
5.51
5.69
mmol/l
3.25
306
3159
76
803
0.93
0.18
1.7
2.3
281.37
318.44
umol/l
3.23
71
761
20
227
0.87
0.18
3.3
8.7
0.96
1.28
mmol/l
1.60
20
222
7
60
1.17
0.18
5.7
2.3
8.20
6.15
pmol/l
—
7
60
78
740
1.07
0.17
1.8
2.1
—
—
—
0
0
13
110
1.19
0.17
1.1
1.0
0.40
1.28
u/ml
—
7
50
75
789
0.94
0.16
1.3
1.3
2.09
11.45
u/ml
2.82
30
349
40
371
1.09
0.15
2.2
2.9
19.32
22.63
%
0.47
14
107
9
78
1.16
0.15
1.7
1.7
—
—
—
0
0
18
159
1.14
0.15
3.8
10.0
25.46
24.66
mmol/l
0.51
18
159
50
530
0.94
0.14
2.2
3.1
429.06
590.19
ng/l
0.33
38
432
74
770
0.95
0.12
4.0
4.0
9.30
10.39
mg/mmol
0.08
45
477
105
1079
0.96
0.10
1.7
1.7
—
—
—
0
0
5
46
1.09
0.09
1.6
1.2
—
—
—
0
0
5
61
0.82
0.08
2.8
2.0
121.60
134.82
g/l
—
5
45
5
63
0.79
0.08
1.4
1.6
—
—
—
0
0
10
88
1.14
0.08
2.0
2.6
24.73
24.33
mmol/l
—
10
88
24
256
0.93
0.08
1.2
1.1
—
—
—
0
0
6
75
0.80
0.07
1.3
1.2
—
—
—
0
0
24
225
1.07
0.07
2.1
3.4
5.91
5.76
kpa
0.32
24
219
104
1063
0.97
0.07
1.3
1.3
0.47
1.66
u/ml
1.66
21
319
11
99
1.11
0.06
1.2
2.6
7.35
10.81
mg/l
1.14
11
94
38
396
0.96
0.06
1.3
1.2
202.09
152.80
u/ml
0.31
15
173
77
787
0.97
0.05
1.6
1.5
19.88
20.78
nmol/l
0.22
72
713
25
238
1.05
0.05
1.8
2.2
84.50
78.76
ml/min/173m2
0.31
16
97
17
160
1.07
0.04
1.1
1.2
—
—
—
0
0
10
109
0.92
0.04
1.2
1.2
—
—
—
0
0
10
109
0.92
0.04
1.2
1.2
—
—
—
0
0
14
132
1.06
0.02
1.6
1.4
—
—
—
0
0
30
291
1.03
0.02
2.1
2.1
0.55
0.63
ug/l
0.30
20
124
10
107
0.93
0.02
1.8
2.0
195.00
232.20
pmol/l
—
10
101
22
222
0.99
0.00
1.5
1.5
—
—
—
0
0
10
99
1.01
0.00
2.2
2.6
1.24
1.25
mg/l
—
10
93
76
757
1.00
0.00
1.9
2.0
—
—
—
0
0
0
9
0.00
0.00
0.0
3.6
—
—
—
0
0
5
52
0.96
0.00
1.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
70.11
—
0
9
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
3.4
—
11.52
—
0
9
0
9
0.00
0.00
0.0
3.4
—
4.64
—
0
9
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
4.6
—
—
—
0
0
0
9
0.00
0.00
0.0
4.6
—
—
—
0
0
6
69
0.87
-0.00
1.3
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
27.00
—
0
5
6
69
0.87
-0.00
1.0
2.4
48.17
203.11
ug/l
—
6
62
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
6
65
0.92
-0.00
1.0
1.2
—
—
—
0
0
8
82
0.98
-0.00
1.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
1.20
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_TERIFLUNOMIDE – Use of teriflunomide
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).